Su Yu-Chi, Shen Yu-Ping, Chang Chih-Ya, Pan Ke-Ting, Huang Shih-Ming, Chen Liang-Cheng
Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei 114, Taiwan.
Graduate Institute of Aerospace and Undersea Medicine, National Defense Medical Centre, Taipei 114, Taiwan.
Int J Mol Sci. 2024 Dec 19;25(24):13608. doi: 10.3390/ijms252413608.
Knee osteoarthritis (OA) is a prevalent degenerative joint disease globally, causing pain, stiffness, and disability. Intravascular laser irradiation of blood (ILIB) has been used for chronic pain and musculoskeletal disease. However, evidence on the clinical benefits and serum biomarkers post-ILIB therapy in knee OA is insufficient. We designed a double-blind randomized controlled trial to evaluate the clinical and biological outcomes of ILIB therapy for knee OA. Seventeen patients with knee OA were randomly assigned to the ILIB and control groups. The outcomes included the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Scale, visual analog scale, and biomarker analysis of interleukin (IL)-6, IL-13, IL-1β, epidermal growth factor, macrophage inflammatory protein-1β, and eotaxin. The measurements were performed at baseline and three days, one month, and three months post-intervention. The ILIB group showed a significant improvement in the WOMAC-pain score at one month of follow-up than the control group. IL-1β levels reduced significantly on day three, one month, and three months, and IL-13 levels reduced on day three and three months during follow-up in the ILIB group. ILIB therapy reduced knee OA pain for one month and significantly reduced serum IL-1β and IL-13 levels, suggesting potential for pain management.
膝骨关节炎（OA）是一种在全球范围内普遍存在的退行性关节疾病，会导致疼痛、僵硬和残疾。血管内激光照射血液（ILIB）已用于治疗慢性疼痛和肌肉骨骼疾病。然而，关于ILIB治疗膝骨关节炎后的临床益处和血清生物标志物的证据并不充分。我们设计了一项双盲随机对照试验，以评估ILIB治疗膝骨关节炎的临床和生物学结果。17名膝骨关节炎患者被随机分配到ILIB组和对照组。结果包括西安大略和麦克马斯特大学骨关节炎指数（WOMAC）量表、视觉模拟量表，以及白细胞介素（IL）-6、IL-13、IL-1β、表皮生长因子、巨噬细胞炎性蛋白-1β和嗜酸性粒细胞趋化因子的生物标志物分析。在基线以及干预后三天、一个月和三个月进行测量。与对照组相比，ILIB组在随访一个月时WOMAC疼痛评分有显著改善。在ILIB组随访期间，IL-1β水平在第三天、一个月和三个月时显著降低，IL-13水平在第三天和三个月时降低。ILIB治疗可减轻膝骨关节炎疼痛一个月，并显著降低血清IL-1β和IL-13水平，提示其在疼痛管理方面具有潜力。
